LEADER 01698oam  2200433 a 450 
001 9910698819503321
005 20090601103256.0
035   $a(CKB)5470000002397674
035   $a(OCoLC)316854515
035   $a(EXLCZ)995470000002397674
100   $a20090324d2009      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aNonprescription drugs$b[electronic resource] $econsiderations regarding a behind-the-counter drug class : report to congressional requesters
210  1$a[Washington, D.C.] :$cU.S. Govt. Accountability Office,$d[2009]
215   $aii, 54 pages $cdigital, PDF file
300   $aTitle from title screen (viewed on Mar. 24, 2009).
300   $a"February 2009."
300   $a"GAO-09-245."
320   $aIncludes bibliographical references.
330   $aGAO is reporting on (1) arguments supporting and opposing a U.S. BTC drug class, (2) changes in drug availability in five countries since 1995 and the impact of restricted nonprescription classes on availability, and (3) issues important to the establishment of a BTC drug class.
517   $aNonprescription drugs 
606   $aDrugs, Nonprescription
606   $aDrugs, Nonprescription$xGovernment policy$zUnited States
606   $aPharmaceutical policy$zUnited States
615  0$aDrugs, Nonprescription.
615  0$aDrugs, Nonprescription$xGovernment policy
615  0$aPharmaceutical policy
801  0$bDID
801  1$bDID
801  2$bESR
801  2$bGPO
906   $aBOOK
912   $a9910698819503321
996   $aNonprescription drugs$93523398
997   $aUNINA